Feed

BLTE

Belite Bio, Inc

BLTE · NASDAQ

$175.35 +0.96% (+$1.66)

1M +9.15%

Market Cap $6.83B

P/E Ratio -

Div. Yield -

ROE 20.57%

Bulios Fair Price

$128.67

26.6% downside

Current Price

$175.35

Undervalued Fair Value Overvalued

According to Bulios Fair Price, BLTE is currently overvalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak

2/9

Valuation

0 /100

Expensive

P/B 8.58x

P/E N/A

EV/FFO N/A

Growth

100 /100

Growing

Book val. growth 164.79%

EPS growth N/A

FCF growth N/A

Profitability

N/A

Gross margin N/A

FCF margin N/A

Net margin N/A

Quality

0 /100

Poor

ROIC 14.92%

Asset turnover 0.00x

ROE 20.57%

Debt

100 /100

Low

Debt/Equity 0.00x

Current ratio 33.71x

Int. coverage N/A

Stability

33 /100

Unstable

Beta -1.24x

Profitable years 0

EPS volatility 53.90%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about BLTE

Online

About the company

Belite Bio is a biotechnology company based in the USA, specializing in the development and production of biological therapeutics for the treatment of various diseases. The company focuses on researching innovative therapies in the fields of oncology, immunology, and other areas of medicine.

Sector

Healthcare

Industry

Biotechnology

CEO

Yu-Hsin Lin

Employees

Headquarters

San Diego

Upcoming events

09 NOV

Earnings

Upcoming earnings report

48d

⌘ K

StockBot Live

Market situation Wall Street

Tech lifts Nasdaq to a record as Dow and S&P 500 slip

Nasdaq +0.23% closes at a record on tech gains. S&P 500 -0.07% and Dow -0.59% slip as oil pares earlier losses.

Ask about this

StockBot knows 80,000+ stocks worldwide